Enveric Biosciences Statistics
Share Statistics
Enveric Biosciences has 10.17M shares outstanding. The number of shares has increased by 308.81% in one year.
| Shares Outstanding | 10.17M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 15.07% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 9.30M |
| Failed to Deliver (FTD) Shares | 15.59K |
| FTD / Avg. Volume | 2.85% |
Short Selling Information
The latest short interest is 330.22K, so 3.32% of the outstanding shares have been sold short.
| Short Interest | 330.22K |
| Short % of Shares Out | 3.32% |
| Short % of Float | 3.68% |
| Short Ratio (days to cover) | 0.31 |
Valuation Ratios
The PE ratio is -162.32 and the forward PE ratio is -0.31.
| PE Ratio | -162.32 |
| Forward PE | -0.31 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 1.43 |
| P/FCF Ratio | -0.2 |
| PEG Ratio | n/a |
Enterprise Valuation
Enveric Biosciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.
| Current Ratio | 1.53 |
| Quick Ratio | 1.53 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -4435.93 |
Financial Efficiency
Return on equity (ROE) is -0.01% and return on capital (ROIC) is -842.19%.
| Return on Equity (ROE) | -0.01% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | -842.19% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.47K |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 28.91K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -73.13% in the last 52 weeks. The beta is 0.47, so Enveric Biosciences 's price volatility has been higher than the market average.
| Beta | 0.47 |
| 52-Week Price Change | -73.13% |
| 50-Day Moving Average | 0.42 |
| 200-Day Moving Average | 0.66 |
| Relative Strength Index (RSI) | 46.72 |
| Average Volume (20 Days) | 547.93K |
Income Statement
In the last 12 months, Enveric Biosciences had revenue of $0 and earned -$17.29K in profits. Earnings per share was $-8.09.
| Revenue | 0 |
| Gross Profit | -408.03K |
| Operating Income | -16.45M |
| Net Income | -17.29K |
| EBITDA | -17.14M |
| EBIT | - |
| Earnings Per Share (EPS) | -8.09 |
Balance Sheet
The company has $2.29M in cash and $0 in debt, giving a net cash position of $2.29M.
| Cash & Cash Equivalents | 2.29M |
| Total Debt | 0 |
| Net Cash | 2.29M |
| Retained Earnings | -96.50M |
| Total Assets | 4.79M |
| Working Capital | 3.50M |
Cash Flow
In the last 12 months, operating cash flow was -$14.09M and capital expenditures -$5.18K, giving a free cash flow of -$14.10M.
| Operating Cash Flow | -14.09M |
| Capital Expenditures | -5.18K |
| Free Cash Flow | -14.10M |
| FCF Per Share | -6.53 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ENVB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2247.22% |
| FCF Yield | -381.93% |
Analyst Forecast
The average price target for ENVB is $10, which is 2677.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 2677.8% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 15, 2022. It was a backward split with a ratio of 1:50.
| Last Split Date | Jul 15, 2022 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | -33.88 |
| Piotroski F-Score | 3 |